Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Common Equity (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Common Equity for 10 consecutive years, with $26.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 59.56% year-over-year to $26.5 million, compared with a TTM value of $26.5 million through Sep 2025, down 59.56%, and an annual FY2024 reading of $46.1 million, down 56.85% over the prior year.
  • Common Equity was $26.5 million for Q3 2025 at Spero Therapeutics, down from $32.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $118.8 million in Q1 2021 and bottomed at $26.5 million in Q3 2025.
  • Average Common Equity over 5 years is $67.3 million, with a median of $64.8 million recorded in 2023.
  • The sharpest move saw Common Equity tumbled 70.97% in 2022, then skyrocketed 65.33% in 2023.
  • Year by year, Common Equity stood at $88.3 million in 2021, then decreased by 13.99% to $75.9 million in 2022, then surged by 40.77% to $106.9 million in 2023, then plummeted by 56.85% to $46.1 million in 2024, then plummeted by 42.56% to $26.5 million in 2025.
  • Business Quant data shows Common Equity for SPRO at $26.5 million in Q3 2025, $32.8 million in Q2 2025, and $33.8 million in Q1 2025.